Participated · Series C · Jun 2026

Float offers a unified platform for Canadian businesses that includes high-limit corporate cards in CAD and USD, automated expense management, next-day bill payments, high-yield business accounts, working capital credit, and cross-border payments built for Canada’s regulatory and bilingual requirements. The company serves more than 7,500 Canadian businesses and reports that since its Series B it has doubled its active customer base, grown revenue over 120%, and seen business account balances rise more than 4.5x. Volumes across five products are up over 100%, and nearly a third of customers now use more than one product. Float operates with a roughly 170-person team and says revenue per employee has increased about 50%. The company is advancing Float Intelligence, its proprietary AI layer, and is using recent funding to expand geographically and increase hiring.

Participated · Equity · Sep 2025

WorkFusion provides pre-built AI Agents that handle labor-intensive, document-heavy processes across anti-money laundering, sanctions screening, Know Your Customer, transaction monitoring and related financial crime compliance workflows. After a 2022 restructuring to focus exclusively on agentic AI, the company leverages more than a decade of work in automation and intelligent document processing. Its technology is currently deployed by 10 of the world’s top 20 banks, where it automates over one million alert hits and eliminates the need for roughly 5,000 full-time-equivalent hours each day. Management reports that customers collectively save about 40,000 hours of manual work daily, scaling compliance team capacity by three- to five-fold. WorkFusion positions its offering as faster, cheaper and more consistent than hiring or outsourcing, mitigating the mounting backlog and cost pressures faced by compliance teams. The company is targeting the $155 billion financial crime compliance operations market and expects accelerating adoption as 85% of financial institutions plan to deploy AI agents in 2025, according to an April 2025 Georgian/NewtonX survey. The recent financing provides capital to expand product capabilities and support global growth.

Participated · Equity · Jan 2025

Darwin CX is a SaaS provider focused on transforming customer experience for publishers, membership organizations, and subscription-based businesses through subscription lifecycle management solutions. The platform offers customized check-out pages, targeted audience offerings, real-time A/B testing, and analytics while enabling clients to control customer data. Darwin CX serves nearly 200 clients and brings over seven years of migration expertise off legacy platforms. The company positions itself as a global leader in subscription lifecycle management and aims to accelerate acquisition, retention, and loyalty for its customers. Recent plans emphasize expanding and enhancing the CX platform and developing new tools to meet evolving subscription-market needs. Financially, Darwin CX has secured additional capital to fund product development and scaling efforts. Darwin CX offers a SaaS platform for the subscription economy that enables brands to accelerate acquisition and retention and increase customer loyalty. The platform provides customized check-out pages, targeted audience offerings, real-time A/B testing, and analytics to help optimize conversions. It enables clients to retain control over customer data to tailor customer experiences. DCX integrates with third-party applications and fulfillment providers to support operations and delivery. The company plans to use the new funding to expand operations, build strategic channel partnerships, and continue investing in its product roadmap. The company is led by CEO Laas Turnbull and is based in Toronto, Canada.

Participated · Series D · Jul 2021

Turnstone Biologics is a clinical-stage biotech pioneering next-generation cancer immunotherapies using two core platforms: a proprietary vaccinia-based oncolytic virus platform and a novel TIL therapy platform. Its lead oncolytic candidate, RIVAL-01/TAK-605, is in the dose-escalation stage of a Phase 1/2a trial conducted in collaboration with Takeda. The vaccinia platform is engineered for enhanced immune stimulation, tumor cell selectivity, large transgene carrying capacity, and both intratumoral and intravenous delivery. The TIL program is designed to enrich for the most relevant tumor-reactive T-cells, preserve broad antigen diversity, and minimize time to treatment, with the lead TIL candidate TIDAL-01 expected to enter the clinic by early 2022. Proceeds from the recently completed financing will be used to advance programs across both platforms. The company states its goal is to extend the benefit of these immunotherapies to a wider range of solid tumor patients underserved by current options. Turnstone Biologics is developing a first‑in‑class oncolytic vaccine platform that functions both as a tumor‑destroying oncolytic agent and as an immune‑stimulating vaccine directed at specific cancer antigens. Its most advanced product is an engineered oncolytic Maraba virus expressing MAGEA3, currently in a Phase I/II monotherapy trial. Completion of that trial is expected in 2017, and Turnstone plans a Phase I/II combination trial with an approved checkpoint inhibitor in NSCLC later this year. Two additional Maraba programs expressing different tumor antigens are expected to enter clinical trials by the end of next year. The company is also advancing neoantigen‑based personalized cancer vaccines and new oncolytic virus development. Turnstone raised a $41.4M Series B to support completion of the ongoing trial and to fund three additional clinical programs. Turnstone Biologics develops novel oncolytic viral immunotherapies aimed at treating advanced and metastatic solid tumours. Its first programs are currently in Phase I/II clinical trials in patients with advanced or metastatic solid tumours. The company is also developing additional oncolytic virus strategies and immunotherapy combination treatments. Turnstone was co-founded by Drs. John Bell, Brian Lichty and David Stojdl. The company is led by CEO Sammy J. Farah, PhD, MBA, and CTO Brian D. Lichty, PhD—appointments enabled by recent investment. Turnstone completed an $11.3M Series A and has follow-on capital committed in excess of $20.0M.

Participated · Equity · Sep 2019

Verafin provides a cloud-based platform for fraud detection and management, BSA/AML compliance, high-risk customer management, and secure information sharing. Nearly 3,000 banks and credit unions use Verafin, and over 1,000 Verafin clients plus 900 additional financial institutions have adopted its FRAMLxchange collaboration platform. The company reported C$100 million in annual recurring revenue as of Q1 2019 (an 87% increase since early 2017), 108% growth in sales bookings between 2017 and 2019, and 102% growth in average deal size over the same period. Verafin consistently achieves a 97% annual customer renewal rate, has signed 25 institutions with over US$5 billion in assets in the last 18 months, and maintains a development team of over 400 developers. Its product emphasizes big-data intelligence, visual storytelling and collaborative investigation to reduce false positives and streamline AML compliance. Management says the company will continue investing in product innovation and customer success as it pursues aggressive growth plans while remaining independent. Verafin is an enterprise FRAML software provider delivering behavior‑based customer risk analytics together with case management and regulatory reporting. Its solutions are delivered via a continuously updated SaaS platform to help clients meet BSA, USA PATRIOT Act, and FATCA requirements. The product suite automates and strengthens clients’ compliance programs and enables an enterprise view of customer activity. Verafin reports a customer base of over 1,100 financial institutions across North America and holds industry endorsements from multiple state bankers’ associations and CUNA, with endorsements in 44 U.S. states. The company positions itself as the exclusive fraud detection and BSA/AML provider for several banking associations. To support continued expansion, Verafin planned to invest the proceeds into its market‑leading SaaS platform and ongoing product enhancements. Verafin provides anti-money laundering (AML) and fraud detection solutions to the financial services industry. The company closed a $5.5m equity financing to support product expansion. Proceeds are intended to help Verafin extend its offering to a wider range of institutions, including the larger bank market. As part of the investment, two RBC Venture Partners executives will join Verafin’s board of directors. Participants in the round included RBC Venture Partners, current investor Killick Capital and founding investor Jamfin. Verafin is based in St. John’s, Newfoundland and Labrador.